Michael Gelband’s Palomar PLMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.25M Buy
+25,698
New +$3.03M 0.02% 633
2026
Q1
Sell
-11,135
Closed -$1.5M 1979
2025
Q4
$1.5M Buy
+11,135
New +$1.36M 0.01% 859
2024
Q2
Sell
-3,972
Closed -$333K 1882
2024
Q1
$333K Buy
+3,972
New +$272K ﹤0.01% 1237
2023
Q4
Sell
-6,203
Closed -$315K 1926
2023
Q3
$315K Buy
6,203
+847
+16% +$46.3K ﹤0.01% 1406
2023
Q2
$311K Buy
+5,356
New +$286K ﹤0.01% 1530
2023
Q1
Sell
-23,645
Closed -$1.07M 2047
2022
Q4
$1.07M Buy
+23,645
New +$1.61M 0.02% 909
2022
Q3
Sell
-4,447
Closed -$286K 2209
2022
Q2
$286K Buy
4,447
+277
+7% +$16.7K ﹤0.01% 1555
2022
Q1
$267K Sell
4,170
-12,139
-74% -$689K ﹤0.01% 1808
2021
Q4
$1.06M Buy
+16,309
New +$1.27M 0.01% 1041
2021
Q2
Sell
-13,904
Closed -$932K 2701
2021
Q1
$932K Buy
+13,904
New +$1.25M 0.01% 959
2020
Q3
Sell
-8,879
Closed -$761K 2128
2020
Q2
$761K Buy
+8,879
New +$589K 0.02% 878
2019
Q4
Sell
-12,084
Closed -$476K 1811
2019
Q3
$476K Buy
+12,084
New +$377K 0.02% 682

Other funds holding PLMR

Michael Gelband's PLMR Position: Q2 2026 in Review

Michael Gelband opened a new position in Palomar (PLMR) in Q2 2026: 25,698 shares worth $3.25M. The stake represents 0.02% of the portfolio and ranks #633 among its holdings. This is a return to the name: Michael Gelband previously reported a position in PLMR as recently as Q4 2025.

Michael Gelband first reported a position in PLMR in Q3 2019 and has held it in 12 quarters since. 339 funds tracked by Wall St. Rank hold PLMR as of Q2 2026.

  • Michael Gelband held 25,698 shares of Palomar worth $3.25M as of Q2 2026.
  • Palomar was a new Michael Gelband position in Q2 2026.
  • Palomar made up 0.02% of Michael Gelband's portfolio in Q2 2026, its #633 holding.
  • Michael Gelband first reported a position in Palomar in Q3 2019 and has held it in 12 quarters since.
  • 339 funds tracked by Wall St. Rank held Palomar as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.